First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2DNovember 18, 2020Diabetes
Lancet panel calls for urgent global action to combat diabetesNovember 13, 2020DiabetesBusiness of Medicine
Don’t miss cardiovascular risk factors in transgender patientsNovember 13, 2020DiabetesTransgender Health
PCI success vs. meds only in diabetes may depend on LDL-C controlNovember 10, 2020DiabetesLipid Disorders
First-of-its kind guideline on lipid monitoring in endocrine diseasesNovember 6, 2020Pituitary, Thyroid & Adrenal DisordersLipid DisordersDiabetesHypercortisolismMenopauseMen's HealthReproductive Endocrinology
